Inhibition of T and B lymphocyte proliferation by rapamycin
J E Kay, L Kromwel, S E Doe, M Denyer, J E Kay, L Kromwel, S E Doe, M Denyer
Abstract
The immunosuppressive macrolide rapamycin shows marked structural similarity to FK-506, and like FK-506 inhibits the activation of cultured T and B lymphocytes at concentrations as low as 10(-10) M. However, rapamycin blocks T-lymphocyte proliferation at a much later stage than FK-506. It also inhibits human, porcine and murine T- and B-lymphocyte activation by all pathways tested, including pathways which are insensitive to FK-506, such as interleukin-2 (IL-2)-mediated proliferation of IL-2-dependent T-cell lines, activation of human peripheral blood T lymphocytes by phorbol ester and anti-CD28 and activation of murine B lymphocytes by bacterial lipopolysaccharide. Thus these two macrolides that bind competitively to the same major intracellular receptor protein inhibit T- and B-lymphocyte activation by quite distinct mechanisms.
References
- Nature. 1989 Oct 26;341(6244):758-60
- J Antibiot (Tokyo). 1975 Oct;28(10):727-32
- Nature. 1989 Feb 2;337(6206):476-8
- Nature. 1989 Feb 2;337(6206):473-5
- Immunol Lett. 1989 Dec;23(2):155-9
- Cell Immunol. 1989 Nov;124(1):175-81
- Immunology. 1989 Nov;68(3):434-5
- Immunology. 1989 Aug;67(4):473-7
- Lancet. 1989 Oct 28;2(8670):1000-4
- J Immunol. 1987 Sep 15;139(6):1797-803
- J Antibiot (Tokyo). 1987 Sep;40(9):1256-65
- Ann Inst Pasteur Immunol. 1987 Jul-Aug;138(4):626-8
- Transplant Proc. 1990 Aug;22(4):1638-41
- Transplantation. 1990 Apr;49(4):798-802
- J Immunol. 1990 Feb 15;144(4):1418-24
- J Immunol. 1990 Jan 1;144(1):251-8
- Transplant Proc. 1990 Feb;22(1):96-9
- Immunology. 1983 May;49(1):153-60
- Immunology. 1982 Sep;47(1):115-21
- Can J Physiol Pharmacol. 1977 Feb;55(1):48-51
- Nature. 1989 Oct 26;341(6244):755-7
Source: PubMed